Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JR-142 in pediatric growth hormone deficiency
jRCT2031200372Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of redalsomatropin alfa and somatropin in growth hormone deficiency (GHD) (3 arms), sponsored by JCR Pharmaceuticals. Primary endpoint: Change in height SDS for chronological age from baseline. Started May 2021; status: completed.
02
Drugs
redalsomatropin alfasomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2031200372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200372.